Bio-Technology General Corp. said Thursday that the IsraeliMinistry of Health has approved its ophthalmic hyaluronic acidproduct.

BioLon, prepared in a ready-to-use syringe, is an aid forsurgical procedures of the eye such as cataract removal,intraocular lens implantation, corneal transplantation andglaucoma filtration. The product helps to retain the shape ofthe dye during such procedures.

The New York company (NASDAQ:BTGC) expects to begin itsproduct sales in Israel within the next few months. BTGC said ithas licensed the product in most of Europe to leadingophthalmic and pharmaceutical companies.

(c) 1997 American Health Consultants. All rights reserved.